We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Moody is a health-tracking application that connects users with customised health, food and fitness advice based on their moods, symptoms and cycles. It endeavours to become a sustainable force for good in women's health. The company argues that women control >80% of household health spend and are 80% more likely than men to use a digital health app. It aims to harness these trends and capitalise on the global remote health care market that is forecast to hit £40 billion by 2025. 'The Moody Month' app featured in publications like Vogue, Grazia and The Guardian. It has witnessed over 136,000 downloads since its Version 1 release in 2019. The app has compiled over 5 million moods to date. The company will use the investment to scale its business globally and reach 1 million subscribers within a four-year time frame.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £142,026
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
WhyBuy is a rental platform that allows a user to rent out items or entities he/she may want to another person. WhyBuy asserts that consumers want to be able to access items for brief periods, and the company aims to be the go-to provider in this segment. It endeavours to save time, space, money and the environment through its business model that is backed by a 100% electric delivery fleet. The company has tested its supply chain to ensure orders are placed despite COVID-19 restrictions. Its app has seen 8000+ downloads from mid-June to end-July 2020 at just over £3 per acquired download across the App Store and Google Playstore. It will use 75% of the investment for marketing, 5% to expand its electric fleet, and 15% as stock and overhead expenses.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £309,260
Cornish Lithium (CL) is a mineral exploration company engaged in the discovery of lithium and other battery metals in Cornwall. It intends to create a 'Battery Metals Hub' in the UK through its efforts. CL has received funding to build the first European Union (EU) pilot lithium extraction plant powered by geothermal waters. It asserts that some of the world's highest grades of lithium are found in geothermal waters. The company has also secured UK Government funding for a new lithium extraction pilot plant in Cornwall. CL has drilled 41 shallow boreholes in a former china clay pit near St Austell, demonstrating the potential to extract lithium from granite. The company will use the investment to accelerate the company towards commercial production of lithium.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £5,199,999
Hussle is one of the UK's top fitness marketplace, providing many flexible fitness opportunities according to your requirement. The company has provided c.2.5M gym visits, raised £12M+ to date, and serviced more than 500k customers. The platform has c.40% of UK gyms and c.3,000 fitness venues. Besides a huge customer base, 10,000 new members are added to the facility each month. It has received a rating of 4.7 stars out of 5 on TrustPilot across 1,500 reviews. So far, Hussle has raised £12M+ from Albion, MMC, Concentric, TechnoGym, and Channel 4. With the proceeds, the company aims at creating a globally trusted fitness brand by enhancing the brand's awareness and by broadening the range of physical activities available on the platform.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,440,500
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £200,000
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,048,396
Bua Fit is easy to use, a simple way to book web application for outdoor fitness classes. It eliminates all the trouble by connecting the trainers to clients for group fitness classes and gives the customers a diversity of trainers. The company has been a finalist in The Great British Entrepreneurial Challenge, has a network of 100 trainers and 42% active user rate since launch. With the proceeds, the company will earn more users, more trainers, more revenue, invest in product development and expand the team.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £205,378
MacRebur uses waste plastics destined for landfill or incineration and adding them into asphalt for road construction and surfacing to extend and enhance the bitumen (fossil fuel) binder. It argues that its carefully selected plastics, taken from the waste stream, are added into roads to improve strength and durability, whilst reducing the quantity of the oil-based bitumen used in a traditional road construction mix. MacRebur asserts that with each km of road laid using its MR products, the company sustainably uses up the equivalent weight of 740,541 one-time-use plastic bags. MacRebur has completed road tests in numerous countries including the UK and Europe, Turkey, Australia, and Japan to name a few. It has also signed agreements with India, the USA, Chile, Estonia, Kuwait, New Zealand, Switzerland, Bahrain, Spain, and Malaysia. The company will use the investment to build its manufacturing plants in five strategic locations across the world.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £3,055,740
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph